198 related articles for article (PubMed ID: 11402324)
1. Bcl-2 expression in F-MuLV-induced erythroleukemias: a role for the anti-apoptotic action of Bcl-2 during tumor progression.
Howard JC; Li Q; Chu W; Zochodne B; Kapoor M; Ung Y; Rosen K; Ben-David Y
Oncogene; 2001 Apr; 20(18):2291-300. PubMed ID: 11402324
[TBL] [Abstract][Full Text] [Related]
2. Loss of p53 in F-MuLV induced-erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence.
Wong KS; Li YJ; Howard J; Ben-David Y
Oncogene; 1999 Sep; 18(40):5525-34. PubMed ID: 10523829
[TBL] [Abstract][Full Text] [Related]
3. p53-independent tumor growth and in vitro cell survival for F-MuLV-induced erythroleukemias.
Howard J; Ung Y; Adachi D; Ben-David Y
Cell Growth Differ; 1996 Dec; 7(12):1651-60. PubMed ID: 8959333
[TBL] [Abstract][Full Text] [Related]
4. Temporal order and functional analysis of mutations within the Fli-1 and p53 genes during the erythroleukemias induced by F-MuLV.
Howard JC; Yousefi S; Cheong G; Bernstein A; Ben-David Y
Oncogene; 1993 Oct; 8(10):2721-9. PubMed ID: 8378083
[TBL] [Abstract][Full Text] [Related]
5. Activation of the erythropoietin gene in the majority of F-MuLV-induced erythroleukemias results in growth factor independence and enhanced tumorigenicity.
Howard JC; Berger L; Bani MR; Hawley RG; Ben-David Y
Oncogene; 1996 Apr; 12(7):1405-15. PubMed ID: 8622856
[TBL] [Abstract][Full Text] [Related]
6. Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage.
Kelley LL; Hicks GG; Hsieh FF; Prasher JM; Green WF; Miller MD; Eide EJ; Ruley HE
Oncogene; 1998 Sep; 17(9):1119-30. PubMed ID: 9764822
[TBL] [Abstract][Full Text] [Related]
7. Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia.
Prasher JM; Elenitoba-Johnson KS; Kelley LL
Oncogene; 2001 May; 20(23):2946-55. PubMed ID: 11420707
[TBL] [Abstract][Full Text] [Related]
8. Insertional inactivation of the p53 gene during friend leukemia: a new strategy for identifying tumor suppressor genes.
Ben-David Y; Lavigueur A; Cheong GY; Bernstein A
New Biol; 1990 Nov; 2(11):1015-23. PubMed ID: 2101628
[TBL] [Abstract][Full Text] [Related]
9. Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV-induced erythroleukemia and human erythroleukemia.
Cui JW; Vecchiarelli-Federico LM; Li YJ; Wang GJ; Ben-David Y
Leukemia; 2009 Jul; 23(7):1311-9. PubMed ID: 19282832
[TBL] [Abstract][Full Text] [Related]
10. Bcl-XL induction during terminal differentiation of friend erythroleukaemia cells correlates with delay of apoptosis and loss of proliferative capacity but not with haemoglobinization.
Hafid-Medheb K; Poindessous-Jazat V; Augery-Bourget Y; Hanania N; Robert-Lézénès J
Cell Death Differ; 1999 Feb; 6(2):166-74. PubMed ID: 10200563
[TBL] [Abstract][Full Text] [Related]
11. FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts.
Pereira R; Quang CT; Lesault I; Dolznig H; Beug H; Ghysdael J
Oncogene; 1999 Feb; 18(8):1597-608. PubMed ID: 10102630
[TBL] [Abstract][Full Text] [Related]
12. Protooncogene expression in normal, preleukemic, and leukemic murine erythroid cells and its relationship to differentiation and proliferation.
Robert-Lézénès J; Meneceur P; Ray D; Moreau-Gachelin F
Cancer Res; 1988 Jul; 48(14):3972-6. PubMed ID: 3164254
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus.
Ben David Y; Prideaux VR; Chow V; Benchimol S; Bernstein A
Oncogene; 1988 Aug; 3(2):179-85. PubMed ID: 2842714
[TBL] [Abstract][Full Text] [Related]
14. p53 transgenic mice: accelerated erythroleukemia induction by Friend virus.
Lavigueur A; Bernstein A
Oncogene; 1991 Dec; 6(12):2197-201. PubMed ID: 1766668
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents.
Kobayashi T; Ruan S; Clodi K; Kliche KO; Shiku H; Andreeff M; Zhang W
Oncogene; 1998 Mar; 16(12):1587-91. PubMed ID: 9569026
[TBL] [Abstract][Full Text] [Related]
16. Bcl-XL protects cancer cells from p53-mediated apoptosis.
Schott AF; Apel IJ; Nuñez G; Clarke MF
Oncogene; 1995 Oct; 11(7):1389-94. PubMed ID: 7478561
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib.
Cervi D; Truong AH; Lee JS; Sukhai N; Li YJ; Koki A; Ben-David Y
Oncogene; 2004 Mar; 23(13):2305-14. PubMed ID: 14743207
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
19. p45(NFE2) is a negative regulator of erythroid proliferation which contributes to the progression of Friend virus-induced erythroleukemias.
Li YJ; Higgins RR; Pak BJ; Shivdasani RA; Ney PA; Archer M; Ben-David Y
Mol Cell Biol; 2001 Jan; 21(1):73-80. PubMed ID: 11113182
[TBL] [Abstract][Full Text] [Related]
20. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
